Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Devi, Latha ^a   Alldred, Melissa J ^a,b   Ginsberg, Stephen D ^a,b   Ohno, Masuo ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; INITIATION FACTOR 2ALPHA; INSULIN; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PROTEIN GGA3; STREPTOZOCIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; PEPTIDE FRAGMENT; SECRETASE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA AMYLOIDOSIS; BRAIN LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYMATIC DEGRADATION; ENZYME PHOSPHORYLATION; INSULIN DEFICIENCY; INSULIN RELEASE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TRANSLATION REGULATION; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; HIPPOCAMPUS; HUMAN; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; TIME;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOSIS; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HIPPOCAMPUS; HUMANS; INSULIN; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; TIME FACTORS;

EID: 84857714157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032792     Document Type: Article

References (55)

1. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
2. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
3. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, et al. (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71: 365-376.
4. Holscher C, (2011) Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 39: 891-897.
5. Park SA, (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 7: 10-18.
6. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105: 423-438.
7. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX, (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225: 54-62.
8. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7: 63-80.
9. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, et al. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247-268.
10. Menon R, Farina C, (2011) Shared molecular and functional frameworks among five complex human disorders: a comparative study on interactomes linked to susceptibility genes. PLoS One 6: e18660.
11. de la Monte SM, Wands JR, (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2: 1101-1113.
12. Gengler S, McClean PL, McCurtin R, Gault VA, Holscher C, (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 33: 265-276.
13. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, et al. (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 1205-1219.
14. McClean PL, Parthsarathy V, Faivre E, Holscher C, (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31: 6587-6594.
15. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, et al. (2008) Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71: 750-757.
16. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, et al. (2010) Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 288: 112-116.
17. Townsend M, Mehta T, Selkoe DJ, (2007) Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282: 33305-33312.
18. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, et al. (2008) Amyloid β oligomers induce impairment of neuronal insulin receptors. FASEB J 22: 246-260.
19. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, et al. (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci USA 106: 1971-1976.
20. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW, (2009) The insulin/Akt signaling pathway is targeted by intracellular β-amyloid. Mol Biol Cell 20: 1533-1544.
21. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, et al. (2010) Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 223: 422-431.
22. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, et al. (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AβPP-overexpressing mice. J Alzheimers Dis 19: 691-704.
23. Wang X, Zheng W, Xie JW, Wang T, Wang SL, et al. (2010) Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5: 46.
24. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. (2006) Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140.
25. Ohno M, Chang L, Tseng W, Oakley H, Citron M, et al. (2006) Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 23: 251-260.
26. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, et al. (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26: 134-145.
27. Kimura R, Ohno M, (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33: 229-235.
28. Ohno M, (2009) Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol Learn Mem 92: 455-459.
29. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O, (2012) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33: 196.e29-196.e40.
30. Devi L, Ohno M, (2010) Genetic reductions of β-site amyloid precursor protein-cleaving enzyme 1 and amyloid-β ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur J Neurosci 31: 110-118.
31. Devi L, Ohno M, (2010) Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One 5: e12974.
32. Chang RC, Wong AK, Ng HK, Hugon J, (2002) Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport 13: 2429-2432.
33. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, et al. (2008) Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron 60: 988-1009.
34. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, et al. (2007) Depletion of GGA3 stabilizes BACE and enhances β-secretase activity. Neuron 54: 721-737.
35. Sarajarvi T, Haapasalo A, Viswanathan J, Makinen P, Laitinen M, et al. (2009) Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem 284: 34433-34443.
36. Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G, (2010) Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem 285: 24108-24119.
37. Santosa C, Rasche S, Barakat A, Bellingham SA, Ho M, et al. (2011) Decreased expression of GGA3 protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein. Neurobiol Dis 43: 176-183.
38. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, et al. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292: 1550-1552.
39. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem 273: 32730-32738.
40. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM, (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4: e7917.
41. Sullivan JM, Alousi SS, Hikade KR, Bahu NJ, Rafols JA, et al. (1999) Insulin induces dephosphorylation of eukaryotic initiation factor 2α and restores protein synthesis in vulnerable hippocampal neurons after transient brain ischemia. J Cereb Blood Flow Metab 19: 1010-1019.
42. Hu C, Cong XD, Dai DZ, Zhang Y, Zhang GL, et al. (2011) Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue. Naunyn Schmiedebergs Arch Pharmacol 383: 309-319.
43. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC, (2002) β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
44. Yang LB, Lindholm K, Yan R, Citron M, Xia W, et al. (2003) Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4.
45. Rossner S, Sastre M, Bourne K, Lichtenthaler SF, (2006) Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog Neurobiol 79: 95-111.
46. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101: 3632-3637.
47. Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, et al. (2010) BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue. J Alzheimers Dis 22: 1111-1122.
48. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, et al. (2007) Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res 1161: 116-123.
49. Holsinger RM, McLean CA, Beyreuther K, Masters C, Evin G, (2002) Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 51: 783-786.
50. Borghi R, Patriarca S, Traverso N, Piccini A, Storace D, et al. (2007) The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging 28: 1009-1014.
51. Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, et al. (2003) β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res Mol Brain Res 116: 155-158.
52. Devi L, Alldred MJ, Ginsberg SD, Ohno M, (2010) Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol Brain 3: 34.
53. Kimura R, Devi L, Ohno M, (2010) Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem 113: 248-261.
54. Alldred MJ, Che S, Ginsberg SD, (2008) Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci 9: 2091-2104.
55. Ginsberg SD, (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439: 147-158.